Novo Nordisk has announced positive headline results from its trial of CagriSema (cagrilintide and semaglutide) in weight loss and blood glucose control.
Data from the phase 3 REIMAGINE 2 trial, part of the global REIMAGINE programme of clinical trials, showed that the weight loss and blood glucose control demonstrated by CagriSema at 68 weeks was superior to those offered by semaglutide. These results were consistent across all tested doses.
The trial evaluated 2,728 people living with type 2 diabetes who were inadequately controlled with metformin with or without an SGLT2 inhibitor. Around 40% of participants were treated with an SGLT2 inhibitor prior to trial initiation.
Those with a baseline body weight of 101kg lost an average of 14.2% after 68 weeks while using, with no weight loss plateau observed at week 68. This is compared to a weight loss of 10.2% for those using semaglutide 2.4mg.
In addition, blood glucose control improved by 1.9%, from a baseline of 8.2%, after 68 weeks for those using CagriSema 2.4mg, compared to 1.76% for those using semaglutide 2.4mg.
CagriSema demonstrated a favourable tolerability and safety profile in the trial, with the most common adverse events being gastrointestinal and the majority of these being mild to moderate in severity.
CagriSema combines the long-acting amylin receptor agonist cagrilintide and the long-acting GLP-1 receptor agonist semaglutide.
Complete results from REIMAGINE 2 will be presented at a scientific conference later in 2026. Following results from the REIMAGINE programme, Novo Nordisk plans to begin regulatory activities regarding CagriSema in type 2 diabetes. CagriSema was previously submitted to the US FDA in December 2025.
Martin Holst Lange, executive vice president, chief scientific officer and head of R&D at Novo Nordisk, said: “By combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction beyond those achieved with each therapy individually.
“The results strengthen our belief that CagriSema could be the first amylin-based combination therapy and a promising treatment option for individuals with type 2 diabetes, that also has a focus on weight loss.”